ADiTx Therapeutics ADTX 深 沪
已收盘 12-19 16:00:00 美东时间
1.19
-0.070
-5.56%
华盛通- 最 高4.15
- 今 开1.23
- 成交量 52.65万股
- 最 低 1.13
- 昨 收 1.26
- 总市值 5322.37万
- 52周最高 12.9199
- 市盈率 静 --
- 换手率 1.18%
- 52周最低 0.02
- 委 比 65.55%
- 总股本 4472.58万
- 历史最高 68.08
- 量 比 0.06
- 振 幅 239.68%
- 历史最低 0.02
- 每 手 1
- 风险率 1.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dow Jumps 150 Points; Jabil Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining around...
12-17 22:39
What Sparked Aditxt (ADTX) Stock's 52% After‑Hours Surge?
Aditxt shares surged 52% after hours following the company's filing of a definitive proxy statement for a special stockholder meeting in January 2026.
12-17 13:14
Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Granite Point Mortgage Trust Inc. (NYSE:GPMT) rose sharply in today's...
2024-09-23 17:46
Aditxt's Adivir, Inc., Agreed To Acquire All Outstanding Class A Common Shares Of Appili Under The Third Amending Agreement; Transaction Is Conditional Upon Aditxt Raising At Least $20M In Financing Before Closing
Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it had entered into a third amending agreement with Appili Therapeutics, Inc. (TSX:APLI, OTC:APLIF) ("Appili"), a biop...
2024-08-21 20:20
Evofem Biosciences Addresses Impact Of GLP-1 Medications On Oral Contraceptive Absorption And Introduces Phexxi As A Non-Oral Solution
As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB:EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of wom...
2024-08-20 20:19
